Bansisons Tea Industries Limited is currently undergoing a fundamental **strategic pivot**, transitioning from its legacy roots in the **Tea and Agriculture** sector toward a high-value future in **Pharmaceuticals, Chemicals, and Life Sciences**. This transformation involves a complete rebranding, a shift in geographical focus from East to West India, and a comprehensive overhaul of its operational mandate. --- ### **Strategic Reorientation: The Pivot to "Novyra Pharmachem"** The company is executing a total transformation of its corporate identity and business scope. This shift is designed to move the entity away from resource-constrained agriculture toward innovation-led research and manufacturing. * **Corporate Rebranding:** In **November 2025**, the Board approved a name change from **Bansisons Tea Industries Limited** to **Novyra Pharmachem Limited** to reflect its new industrial focus. * **Main Object Clause Amendment:** The company has amended its **Memorandum of Association (MOA)** to include: * **Manufacturing & Formulation:** Production of **Active Pharmaceutical Ingredients (APIs)**, bulk drugs, intermediates, and specialty chemicals. * **Biotechnology & Nutraceuticals:** Development of advanced biopharmaceuticals and health supplements. * **Sustainable Manufacturing:** A commitment to **Green Chemistry** and **eco-efficient** production technologies to minimize waste. * **Asset Monetization:** To fund this expansion, the Board approved the sale of the company’s **West Bengal undertaking and land** on a **going concern basis** (under **Section 180(1)(a)**). Proceeds are earmarked for reducing operational inefficiencies and fueling the pharmaceutical entry. --- ### **Geographical Relocation and Infrastructure** The company has strategically relocated its base of operations to tap into India’s primary chemical and pharmaceutical corridor. * **Registered Office Shift:** Effective **December 24, 2025**, the registered office moved from **West Bengal** to **Gujarat (Surat)**. * **New Corporate Identity:** Following the move, the company was issued a new **CIN: L15520GJ1987PLC171085**. * **Strategic Rationale:** The move to Gujarat is intended to provide superior access to **logistics hubs**, a highly **skilled workforce**, and proximity to the **Western Indian markets** of Gujarat, Maharashtra, and Rajasthan. --- ### **New Service Models and Technical Capabilities** The company’s future operational framework is built around a diversified life sciences service model: | Service Category | Operational Scope | | :--- | :--- | | **CRO (Contract Research)** | Collaborative research, medicinal chemistry, and analytical testing. | | **CDMO (Contract Development)** | End-to-end product development, scale-up, and pilot plant operations. | | **CMO (Contract Manufacturing)** | Large-scale production of pharmaceutical intermediates and finished products. | | **Technical Services** | Toxicological studies, regulatory support, IP services, and chemical consultancy. | **Compliance Standards:** The company is aligning its infrastructure to meet **GMP (Good Manufacturing Practice)**, **GLP (Good Laboratory Practice)**, and **ISO Standards** to serve global regulatory markets. --- ### **Legacy Operations: Agriculture and Tea** While the company is transitioning, its historical core remains in the tea industry, which currently dictates its "Single Segment" reporting status. * **Core Activities:** Trading in **Agriculture Products**, tea plantation, production, and marketing. * **Sector Challenges:** The legacy business faces significant headwinds, including **limited land availability**, high dependence on **climatic and soil conditions**, and a declining trend in **export quantum and value**. * **Regulatory Pressure:** Profitability in this segment is constrained by a **multiplicity of taxes** and stringent government control mechanisms. --- ### **Financial Reporting and Audit History** The company maintains financial disclosures in accordance with **Ind AS** and **SEBI (LODR) Regulations, 2015**. * **Audit Opinions:** The company received **Unmodified ("True and Fair View")** opinions for both **FY 2023-24** and **FY 2024-25**. * **Auditor Transition:** Recent audits were conducted by **DG MS & Co.** (FY 24-25) following the tenure of **Bijan Ghosh & Associates** (FY 23-24). * **Internal Controls:** The company utilizes an **Internal Audit Charter** and a system of **self-certification** by process owners, overseen by the **Audit Committee**. --- ### **Critical Risk Factors and Compliance Deficiencies** Investors should note significant regulatory and operational risks that have impacted the company’s standing: **1. Regulatory Non-Compliance & Surveillance:** * **ESM Stage-I:** The company has been under **BSE’s Enhanced Surveillance Measure (ESM) Stage-I** since **June 02, 2023**. * **Listing Violations:** Failure to maintain a functional corporate website (**Reg 46**) and failure to publish board meeting notices or financial results in newspapers (**Reg 47**). * **Insider Trading:** Non-compliance with **Structured Digital Database (SDD)** requirements under SEBI (Prohibition of Insider Trading) regulations. **2. Governance and Shareholding Issues:** * **Board Vacancies:** Contravention of **Section 149** of the Companies Act; an **Executive Director** vacancy remained unfilled beyond the statutory three-month limit following a term end in **March 2023**. * **Demat Discrepancies:** **100% of promoter holdings** are not yet in dematerialized form. * **Capital Disclosure:** Audited books show **partly paid-up shares** that were not accurately reflected in quarterly shareholding patterns submitted to the BSE. **3. Operational Vulnerabilities:** * **Data Loss:** A **total loss of data** due to a computer crash in **October 2023** delayed financial finalization and necessitated a 3-month extension for the 2023 AGM. * **Missing Filings:** Several statutory forms (**MGT-14, AOC-4, MGT-7**) for the 2023 period were noted as missing from the MCA database in recent reviews. --- ### **Risk Management Framework** The company categorizes and monitors risks through a structured internal framework: * **Commodity Price Risk:** Managed via **forward booking** and **vendor development** to mitigate raw material volatility. * **Strategic Risk:** Capital expenditure and capacity expansion are subject to defined Board approval processes. * **Human Resources Risk:** Addressed through a **strategic talent management system** to prevent the loss of key personnel during the transition. * **Liquidity Risk:** While auditors issued an unmodified opinion, they noted that the absence of "material uncertainty" regarding one-year liability coverage is **not a guarantee** of long-term debt discharge.